DEA Celebrates 50-Year Anniversary While Failing To Win The Drug War

July 8, 2023 ·

The Drug Enforcement Administration (DEA) celebrated its 50th anniversary this week—marking a half century of enforcing criminalization laws that have failed to fulfill the mission to eradicate drugs at the same time that nearly half of the country has legalized marijuana and psychedelics reform is also booming.

Since its founding on July 1, 1973 through an executive order issued by President Richard Nixon, DEA’s budget has swelled and its workforce has expanded—but illicit drugs remain widely accessible across the U.S., with waves of new, even deadlier substances continually emerging under prohibition while others like cannabis have been increasingly legalized at the state level.

“Over the past 50 years, DEA has worked to keep American communities safe and healthy by preventing criminal drug networks and drug-related violence and deaths,” the agency, which replaced the former Bureau of Narcotics and Dangerous Drugs five decades ago, said in a press release about its anniversary.

Yet while the agency continues to make thousands of arrests every year, while destroying controlled substances and seizing assets along the way, the anniversary also serves as a reminder that the war on drugs has been one of the costliest and least successful campaigns to be waged by the federal government. Indeed, more than 100,000 Americans died from drug overdoses in 2021 alone—a record high.

And when it comes to drug trafficking, even major disruptions to international enterprises haven’t stymied the flow of the substances. The trends for each drug have simply fluctuated, as the U.S. Sentencing Commission (USSC) shows. From 2018 to 2022, the percent of heroin trafficking cases declined by 37.4 percent—but the percent of fentanyl cases skyrocketed 435.4 percent, for example.

Meanwhile, reform advocates have made massive strides in combating the drug warrior narrative and affecting change at the local and state levels, with 23 states now having legalized marijuana for adult use and two having ended prohibition on certain psychedelics.

Federal reform has lagged, comparatively, but DEA itself has now found itself in a position where it will have to reconcile the science on cannabis and reach a decision about whether to remove it from Schedule I of the Controlled Substances Act (CSA) under a directive issued by President Joe Biden last year.

DEA hasn’t been entirely obstinate amid the paradigm shift in public opinion and policy. It’s routinely increased production quotas for marijuana and psychedelics for research purposes as interest within the scientific community expands. And it also ended a long-standing monopoly on cannabis cultivation for research by approving additional manufacturers.

Meanwhile, the agency also lost legal control over hemp containing up to 0.3 percent THC following the passage of the 2018 Farm Bill, and it is now working to finalize rules on synthetic cannabinoids like delta-8 THC. DEA has also faced numerous lawsuits over everything from psilocybin scheduling to the way it processes Freedom of Information Act (FOIA) requests.

As Reason reported this week, DEA’s own museum is rife with subtle acknowledgements that the agency has failed to win the drug war. Last year, the museum even publicly recognized the fact that racially discriminatory drug laws are partly responsible for the agency’s own founding.

Many congressional lawmakers have sharply criticized the criminalization model for drugs—especially marijuana. Some Democrats have also introduced legislation to federally decriminalize all currently illici substances and shift to a public health-centered approach to addiction.

But in the interim, there’s no sign that Congress will do away with DEA anytime soon despite its critical—and increasingly widely acknowledged—shortcomings. The question is whether it will work to be a partner in science-based efforts to modernize federal drug policy or continue the 50-year-long game of prohibitionist Whac-A-Mole. (Full Story)

In category:Federal Policy
Next Post

The Military to Stop Testing for Marijuana? - Just Like Amazon, the Military May Stop Testing for Cannabis

f you can't beat them, join them!  Just like major companies like Amazon that did away with marijuana testing in order to get more eligible employees, the US military may drop marijuana testing for soliders as it tries to get more recruits…
Previous Post

Senators Aim For Marijuana Banking Vote This Month In Committee, With Republican Sponsor ‘Open’ To Including Expungements Provisions

Key senators say they’re aiming to hold a committee vote on a marijuana banking bill when they return from the July 4th recess—though at least one section of the measure remains in dispute amid negotiations. And when it comes to…
Random Post

The Big Benefits of Cannabis Triploids

All good things come in threes, but cultivators are just beginning to understand how this famed Latin principle applies to cannabis genetics. The weed we know and love is typically constructed with a pair of chromosomes (diploid) and a limited number…
Random Post

GOP Committee Chairman Seeks To Scale Back Bill On Removing Federal Marijuana Employment Barriers Ahead Of This Week’s Vote

The chairman of a key House committee is proposing to significantly scale back a bipartisan bill on marijuana-related protections for federal workers that’s scheduled for a vote in his panel this week. The House Oversight and Accountability Committee is scheduled to…
Random Post

Congressional Committee Approves GOP-Led Marijuana ‘Pilot Program’ And Psychedelics Study Amendments To Military Bill

A congressional committee has approved a large-scale defense bill that includes GOP-led provisions to create a medical marijuana “pilot program” and require a study into the therapeutic potential of psychedelics for active duty military members under the U.S. Department of…
Random Post

Is PGR Cannabis Worth the Weight?

An increasingly competitive market with slim profit margins means cannabis cultivators are always looking for ways to optimize output. But without hindsight, the line between streamlined success and an erroneous misstep can prove difficult to identify. Synthetic plant growth regulators (PGRs) are being…